<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Ritonavir: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int400-ritonavir.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int400-ritonavir.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int400-ritonavir.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int391-antivirals.htm">Antivirals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int843-nevirapine.htm" title="Previous: Nevirapine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int791-saquinavir.htm" title="Next: Saquinavir">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Ritonavir</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Ritonavir</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>alfentanil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int30-alfuzosin.htm">Alfuzosin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>alfuzosin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>alprazolam</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>amiodarone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>SSRIs</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int304-antihistamines-non-sedating.htm">Antihistamines, Non-sedating</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>non-sedating antihistamines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>antipsychotics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span> <span>ritonavir</span> <span>given with</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int167-azithromycin.htm">Azithromycin</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>azithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span> <span>ritonavir</span> <span>given with</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>bosentan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int496-budesonide.htm">Budesonide</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>budesonide</span> <span>(including inhaled, intranasal, and rectal<span>budesonide</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int87-buprenorphine.htm">Buprenorphine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>buprenorphine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>clarithromycin</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>ritonavir</span> <span>advises avoid concomitant use with</span> <span>clozapine</span> <span>(increased risk of toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>dexamethasone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int714-dexamfetamine.htm">Dexamfetamine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>dexamfetamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int90-dextropropoxyphene.htm">Dextropropoxyphene</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>dextropropoxyphene</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>diazepam</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>disopyramide</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>docetaxel</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span></span> <span>ritonavir</span> <span>increases toxicity of</span> <span>efavirenz</span> <span>, monitor liver function tests</span>  </p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span> <span>ritonavir</span> <span>given with</span> <span>ergotamine and methysergide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>fentanyl</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of fesoterodine advises dose reduction when </span> <span>ritonavir</span> <span>given with</span> <span>fesoterodine</span> <span>—consult <span>fesoterodine</span> product literature</span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>flecainide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span> <span>ritonavir</span> <span>increased by</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int416-flurazepam.htm">Flurazepam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>flurazepam</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int497-fluticasone.htm">Fluticasone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of inhaled and intranasal</span> <span>fluticasone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int163-fusidic-acid.htm">Fusidic Acid</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span> <span>ritonavir</span> <span>given with</span> <span>fusidic acid</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>indinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>combination of </span> <span>ritonavir</span> <span>with</span> <span>itraconazole</span> <span>may increase plasma concentration of either drug (or both)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>combination of </span> <span>ritonavir</span> <span>with</span> <span>ketoconazole</span> <span>may increase plasma concentration of either drug (or both)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>lamotrigine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>lercanidipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation—avoid concomitant use of oral<span>midazolam</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int98-morphine.htm">Morphine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>morphine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>NSAIDs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td><p><span>combination of </span> <span>ritonavir</span> <span>with</span> <span>nelfinavir</span> <span>may increase plasma concentration of either drug (or both)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>nilotinib</span> <span>—manufacturer of <span>nilotinib</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>olanzapine</span> <span>—consider increasing dose of <span>olanzapine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int517-paclitaxel.htm">Paclitaxel</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>paclitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>paroxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>pethidine</span> <span>, but increases plasma concentration of toxic metabolite of <span>pethidine</span> (avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly enhances anticoagulant effect of</span> <span>phenindione</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>ritonavir</span> <span>possibly reduced by</span> <span>phenytoin</span> <span>, also plasma concentration of <span>phenytoin</span> possibly affected</span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int78-piroxicam.htm">Piroxicam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>piroxicam</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int486-prednisolone.htm">Prednisolone</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>prednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>propafenone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span> <span>ritonavir</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>rivaroxaban</span> <span>—manufacturer of <span>rivaroxaban</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span> <span>ritonavir</span> <span>given with</span> <span>rosuvastatin</span> <span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>significantly increases plasma concentration of</span> <span>sildenafil</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>ritonavir</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1020-solifenacin.htm">Solifenacin</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>solifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ritonavir</span> <span>reduced by</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>tadalafil</span> <span>—manufacturer of <span>tadalafil</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span> <span>ritonavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>accelerates metabolism of</span> <span>theophylline</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ticagrelor</span> <span>—manufacturer of <span>ticagrelor</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int275-tolbutamide.htm">Tolbutamide</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>tolbutamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int255-trazodone.htm">Trazodone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>trazodone</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span> <span>ritonavir</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>vardenafil</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1002-vinblastine.htm">Vinblastine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>vinblastine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>vinflunine</span> <span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>voriconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>may enhance or reduce anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int425-zolpidem.htm">Zolpidem</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>zolpidem</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span>  </p></td><td></td></tr></tbody></table><p><strong>Ritonavir</strong> belongs to <strong>Antivirals</strong> but <strong>Antivirals</strong> has no interactions information.</p></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int843-nevirapine.htm">Previous: Nevirapine</a> | <a class="top" href="bnf_int400-ritonavir.htm#">Top</a> | <a accesskey="]" href="bnf_int791-saquinavir.htm">Next: Saquinavir</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>